Technical Analysis for TCBP - TC BioPharm (Holdings) plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.23% | |
Wide Bands | Range Expansion | 1.23% | |
Oversold Stochastic | Weakness | 1.23% | |
Lower Bollinger Band Walk | Weakness | 0.53% | |
Wide Bands | Range Expansion | 0.53% | |
Oversold Stochastic | Weakness | 0.53% | |
Stochastic Buy Signal | Bullish | 5.09% | |
Lower Bollinger Band Walk | Weakness | 5.09% | |
Inside Day | Range Contraction | 5.09% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 9 hours ago |
Down 5% | about 9 hours ago |
Down 3% | about 9 hours ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Solid Tumors Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Cell Therapy Acute Myeloid Leukemia Cell Biology Treatment Of Acute Myeloid Leukemia T Cells Immunotherapy Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Solid Tumors Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Cell Therapy Acute Myeloid Leukemia Cell Biology Treatment Of Acute Myeloid Leukemia T Cells Immunotherapy Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 19.6 |
52 Week Low | 0.7212 |
Average Volume | 1,130,424 |
200-Day Moving Average | 3.61 |
50-Day Moving Average | 1.16 |
20-Day Moving Average | 0.97 |
10-Day Moving Average | 0.84 |
Average True Range | 0.10 |
RSI (14) | 36.31 |
ADX | 20.93 |
+DI | 19.49 |
-DI | 22.28 |
Chandelier Exit (Long, 3 ATRs) | 0.92 |
Chandelier Exit (Short, 3 ATRs) | 1.02 |
Upper Bollinger Bands | 1.23 |
Lower Bollinger Band | 0.70 |
Percent B (%b) | 0.25 |
BandWidth | 55.26 |
MACD Line | -0.10 |
MACD Signal Line | -0.10 |
MACD Histogram | -0.0055 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.95 | ||||
Resistance 3 (R3) | 0.95 | 0.90 | 0.93 | ||
Resistance 2 (R2) | 0.90 | 0.87 | 0.91 | 0.93 | |
Resistance 1 (R1) | 0.87 | 0.86 | 0.89 | 0.87 | 0.92 |
Pivot Point | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 |
Support 1 (S1) | 0.79 | 0.80 | 0.81 | 0.80 | 0.75 |
Support 2 (S2) | 0.75 | 0.78 | 0.75 | 0.74 | |
Support 3 (S3) | 0.71 | 0.75 | 0.74 | ||
Support 4 (S4) | 0.72 |